Parkinson's Disease Medication Explained: A Practical Guide for Non-Neurologists
By Dr Will Bierrum, Neurology Registrar and Founder of MedXStart - the success platform for modern doctors, covering medical education, exams, interviews, technology, and ventures beyond medicine.
Parkinson's disease medication confused me when I first started in neurology. So many drug classes, so many brand names, so many formulations. If you are a GP, junior doctor, nurse or allied health professional who has ever stood at a prescribing screen feeling uncertain about a patient's Parkinson's medications, this post is for you.
The goal is not to turn you into a specialist. The goal is pattern recognition — understanding what each drug class does and why it matters when you are looking after a patient on the ward or in clinic.
The One Principle That Makes It All Make Sense
Parkinson's disease causes the progressive loss of dopamine-producing cells in the substantia nigra. Every drug class used in Parkinson's disease works to either replace, mimic, or preserve dopamine in different ways.
Once you understand this, the classes stop feeling random and start making sense as a system.
Levodopa — The Gold Standard
Levodopa is the most effective symptomatic treatment for Parkinson's disease and remains the cornerstone of management, particularly in older patients. It crosses the blood-brain barrier and converts directly into dopamine.
It is always given with a peripheral decarboxylase inhibitor — either carbidopa or benserazide — to prevent it breaking down in the bloodstream before it reaches the brain and to reduce nausea. You will see this combination under brand names such as Sinemet (co-careldopa) and Madopar (co-beneldopa).
The catch: Long-term use leads to motor complications including wearing-off fluctuations and dyskinesias. This is important to know when reviewing any patient on long-term levodopa.
On formulations: Standard release and modified release preparations are not interchangeable dose-for-dose. Modified release is mainly used at night to provide overnight coverage. If you are ever unsure about formulations, check with pharmacy before prescribing.
Dopamine Agonists — The Mimics
Dopamine agonists bypass the need for conversion by stimulating dopamine receptors directly. Examples include ropinirole, pramipexole and the rotigotine transdermal patch.
They are frequently used as first-line treatment in younger patients to delay starting levodopa and reduce the risk of dyskinesias. However, they have a weaker antiparkinsonian effect than levodopa.
Do not miss this: Impulse control disorders. Gambling, hypersexuality and compulsive behaviours are well-recognised side effects of dopamine agonists. Patients rarely volunteer this information — you have to ask directly. NICE guideline NG71 highlights this as a key communication priority.
MAO-B Inhibitors — The Preservers
MAO-B inhibitors block the enzyme that breaks down dopamine in the brain, preserving what is already there. Examples include selegiline, rasagiline and safinamide.
They offer a modest symptomatic effect and can be used alone in early disease to delay the need for levodopa by a few months, or added on later to smooth motor fluctuations. They are generally well tolerated.
COMT Inhibitors — The Extenders
COMT inhibitors block an enzyme that breaks down levodopa in the peripheral bloodstream, extending its half-life and smoothing out wearing-off periods between doses. Examples include entacapone and opicapone.
Key point: COMT inhibitors only work alongside levodopa. They have no effect on their own. If a patient on levodopa tells you their symptoms return before their next dose is due, that is wearing off — and COMT inhibitors are typically added in this situation.
Amantadine — The Antidyskinetic
Originally an antiviral drug, amantadine has a mixed mechanism including dopamine release and NMDA receptor antagonism. It can be used as mild early treatment, but its most valuable modern role is reducing levodopa-induced dyskinesias.
If a patient on long-term levodopa has troublesome involuntary movements, amantadine is worth knowing about. Side effects include ankle swelling and livedo reticularis — a mottled skin rash.
What To Do When Your Parkinson's Patient Is NBM
This is a medication safety issue that affects every ward doctor.
Never stop Parkinson's medication abruptly. It can cause severe rigidity, confusion and a significant clinical deterioration. If a patient cannot swallow, you need to find an alternative route urgently.
The rotigotine patch is one option used to maintain dopaminergic therapy when the oral route is unavailable, but look up the conversion before prescribing and always involve pharmacy early.
The most important rule: Parkinson's medication must be given on time. Delays matter more than in most other conditions. Contact the pharmacist and the Parkinson's nurse specialist early and do not wait until doses have been missed. Parkinson's UK has excellent resources on medication safety for inpatients.
The Pattern That Matters
Understanding Parkinson's medication is not about memorising brands. It is about understanding what each class does. For each drug think, does it replace, mimic, preserve or extend and recognise which clinical situation calls for which approach.
If you want to develop this kind of systematic, pattern-based approach to neurology, my Neurology Pattern Recognition Guide is available now at medxstart.co.uk. It is designed to help non-neurologists think clearly about complex neurology.
Frequently Asked Questions
What is the first-line treatment for Parkinson's disease? Levodopa is the most effective symptomatic treatment for Parkinson's disease and is typically first-line in older patients. In younger patients, dopamine agonists are often used first to delay levodopa and reduce the risk of long-term motor complications such as dyskinesias.
What is wearing off in Parkinson's disease? Wearing off refers to the return of Parkinson's symptoms before the next dose of levodopa is due. It occurs as a result of motor fluctuations associated with long-term levodopa use. COMT inhibitors and MAO-B inhibitors can be added to levodopa to extend its effect and reduce wearing off.
What should you do if a Parkinson's patient cannot swallow their medication? Never stop Parkinson's medication abruptly. Seek an alternative route urgently — the rotigotine transdermal patch is one option. Involve pharmacy and the neurology or Parkinson's nurse specialist team early. Parkinson's medications must be given on time as delays can cause rapid clinical deterioration.
What are the side effects of dopamine agonists in Parkinson's disease? Dopamine agonists including ropinirole, pramipexole and rotigotine can cause impulse control disorders such as pathological gambling, hypersexuality and compulsive shopping. They can also cause hallucinations and excessive daytime somnolence. Patients should be counselled about these risks and asked directly about impulse control symptoms at each review.
What is the difference between Sinemet and Madopar? Both Sinemet and Madopar are levodopa preparations. Sinemet contains levodopa combined with carbidopa (co-careldopa), while Madopar contains levodopa combined with benserazide (co-beneldopa). Both combine levodopa with a peripheral decarboxylase inhibitor to prevent peripheral breakdown and reduce side effects. They are not directly interchangeable and preparations vary in the ratio of levodopa to inhibitor.
What is amantadine used for in Parkinson's disease? Amantadine is primarily used to reduce levodopa-induced dyskinesias in patients on long-term levodopa therapy. It has a mixed mechanism of action including dopamine release and NMDA receptor antagonism. Side effects include ankle swelling and livedo reticularis.
Dr Will Bierrum is a neurology registrar and founder of MedXStart — the success platform for modern doctors, covering medical education, exams, interviews, technology, and ventures beyond medicine. medxstart.co.uk
This post is for educational purposes only. It does not constitute clinical guidelines or medical advice. Always refer to local guidelines and senior colleagues when making clinical decisions.